General
General Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
General Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) said its joint venture CoSara Diagnostics was invited to the 2nd Advanced TB Diagnostics Course in Chennai, India, held Dec 15–19, 2025 at ICMR–NIRT.
The multi-day workshop, hosted with McGill International TB Centre and global partners, brings national TB programs, diagnostics developers, industry and experts from WHO, Gates Foundation, FIND and academic institutions to review the diagnostics value chain, new technologies, cost-effectiveness modeling, policy development and strategies to close the TB case-finding gap across the South‑East Asian Region.
Loading…
Loading translation…
Market Reaction
15 min delay
8 Alerts
+13.89%
Since News
$0.30
Last Price
$0.27
$0.30
Day Range
+$2M
Valuation Impact
$18M
Market Cap
0.4x
Rel. Volume
Following this news, CODX has gained 13.89%, reflecting a significant positive market reaction.
Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility.
The stock is currently trading at $0.30.
This price movement has added approximately $2M to the company’s valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Workshop dates
December 15-19, 2025
2nd Advanced TB Diagnostics Course in Chennai, India
Program length
Five-day program
Advanced TB diagnostics and implementation workshop
Course edition
2nd Advanced TB Diagnostics Course
Regional capacity-building workshop for SEAR countries
Market Reality Check
$0.2620
Last Close
Volume
Volume 1,804,482 is 13% above the 20-day average of 1,592,260, signaling elevated interest ahead of this JV-focused announcement.
normal
Technical
CODX at $0.262 is trading below its 200-day MA of $0.35 and remains 83.1% under its 52-week high.
Peers on Argus
CODX gained 6.46% while peers showed mixed moves (e.g., INBS up 10.58%, AIMD down 6.64%), indicating a stock-specific reaction rather than a coordinated medical devices sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Positive | +6.5% |
In silico analysis confirmed Logix Smart ABC coverage of H3N2 mutation. |
|
| Dec 09 | Positive | +4.5% |
Conference presentation on portable Co-Dx PCR platform and AI integration. |
|
| Dec 08 | Positive | -7.4% |
CoSara VIROCON presence and Phase I/II MTB and HPV preclinical data. |
|
| Nov 20 | Positive | -5.8% |
Address on MTB test adoption and potential India/South Africa rollout. |
|
| Nov 18 | Positive | +13.4% |
Initiation of clinical evaluations for upper respiratory multiplex POC test. |
Pattern Detected
News tied to platform progress or JV activity often triggers sizable moves in both directions, with a slight tilt toward positive alignment on more recent technical or platform updates.
Recent Company History
Over the past month, CODX has issued multiple updates on its Co-Dx PCR platform and tuberculosis/respiratory testing pipeline. Events on Nov 18 and Nov 20 highlighted clinical evaluations and MTB test planning, while Dec 8 and Dec 17 detailed CoSara’s role and influenza assay performance. Today’s TB diagnostics workshop participation further reinforces the company’s focus on TB and point-of-care expansion, particularly via its Indian joint venture.
Market Pulse Summary
The stock is surging +13.9% following this news. A strong positive reaction aligns with CODX’s pattern of sizable moves on JV and platform news, as seen in prior events with moves up to 13.37%. Participation in a regional TB diagnostics course reinforces CoSara’s positioning in India-focused tuberculosis testing. However, past divergence on seemingly positive TB and conference updates suggests that enthusiasm has not always been durable, so investors have historically reassessed these spikes against broader fundamentals.
Key Terms
tuberculosis
medical
“address emerging needs in tuberculosis detection, research, and implementation”
A contagious bacterial infection that most often attacks the lungs and can range from a mild, slow-developing illness to a severe, long-lasting disease. It matters to investors because its prevalence, treatment options, diagnostic tests and public health policies drive demand for medicines, vaccines and medical services; like a smoldering fire, outbreaks and progress in therapies can quickly change market size, regulatory priorities and company valuations.
diagnostics value chain
technical
“The workshop includes sessions covering the full diagnostics value chain, highlights”
The diagnostics value chain is the series of steps that take a medical test from idea to use: research and development, regulatory approval, manufacturing, distribution, laboratory or point‑of‑care testing, and reporting of results. Think of it like an assembly line that not only builds a product but also delivers and explains it to the customer. Investors care because strengths or bottlenecks at any step affect costs, speed to market, revenue predictability and regulatory risk, all of which shape returns.
AI-generated analysis. Not financial advice.
, /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (“CoSara”), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR). The event will take place December 15-19, 2025 at the ICMR–National Institute for Research in Tuberculosis (NIRT) located in
Hosted by ICMR-NIRT in partnership with the McGill International TB Centre and other global health organizations, the multi-day workshop brings together leading experts, national TB programs, diagnostics developers and industry partners to address emerging needs in tuberculosis detection, research, and implementation. The workshop includes sessions covering the full diagnostics value chain, highlights new technologies in the innovation pipeline, examines cost-effectiveness modeling and evidence-based policy development, and explores practical strategies to close the TB case-finding gap across SEAR nations.
The five-day program will also feature presentations and panel discussions led by national and international faculty, including experts from WHO, The Gates Foundation, FIND,
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-invited-to-participate-in-2nd-advanced-tb-diagnostics-course-in-chennai-india-302645600.html
SOURCE Co-Diagnostics
General FAQ
What is CoSara Diagnostics’ role at the 2nd Advanced TB Diagnostics Course in Chennai Dec 15–19, 2025?
CoSara Diagnostics was invited to participate among industry partners to present and engage in sessions across the diagnostics value chain.
How does Co-Diagnostics (CODX) benefit from CoSara’s participation in the Chennai TB diagnostics workshop?
Participation increases CoSara’s visibility with national TB programs and global health organizations, supporting networking and technology exposure.
Which organizations and experts will present at the Dec 15–19, 2025 TB diagnostics course in Chennai?
Presenters include WHO, Gates Foundation, FIND, McGill International TB Centre, Boston University and India’s central TB institutions.
What topics will the 2nd Advanced TB Diagnostics Course in Chennai cover for CODX/CoSara?
The workshop covers the diagnostics value chain, new technologies, cost-effectiveness modeling, evidence-based policy, and case-finding strategies.
Will CoSara present a technology pitch or product at the Chennai workshop?
The workshop program includes industry technology pitches, and CoSara was invited to participate among industry innovators.